Search

Search Results

• S-MAPA: bridging the gap in psoriasis severity assessment

  Trang Thi Thuy Vu, Chuyen Thi Hong Nguyen, Trung The Van

  28-05-2025

  https://doi.org/10.4081/dr.2025.10231

  751

  PDF: 357

  HTML: 33

• Efficacy of tildrakizumab 200 mg for treating difficult-to-treat patient populations with moderate-to-severe plaque psoriasis

  Paolo Dapavo, Matteo Megna, Marina Talamonti

  09-08-2024

  https://doi.org/10.4081/dr.2024.9999

  1850

  PDF: 745

  HTML: 109

• Efficacy and safety of risankizumab in patients with erythrodermic and sub-erythrodermic psoriasis: a case series

  Andrea D'Arino, Maria Concetta Fargnoli, Pasquale Frascione, Chiara Assorgi, Annunziata Dattola, Viviana Lora, Matteo Megna, Flavia Pigliacelli, Emanuele Vagnozzi, Diego Orsini

  30-07-2025

  https://doi.org/10.4081/dr.2025.10379

  576

  PDF: 394

  HTML: 15

• Intra-class switch among interleukin-17 inhibitors for the treatment of plaque psoriasis: a single-center experience

  Gioele Ghezzi, Luciano Ibba, Luigi Gargiulo, Alessandra Narcisi, Antonio Costanzo, Mario Valenti

  12-11-2024

  https://doi.org/10.4081/dr.2024.10080

  1374

  PDF: 750

  HTML: 47
• 

  Real-world treatment patterns, patient-reported outcomes, and effectiveness of flexible-dosing etanercept in patients with plaque psoriasis in Greece

  Dimitris Rigopoulos, Aikaterini Patsatsi, Christina Antoniou, Dimitrios Sotiriadis, Angeliki Roussaki-Schulze, Nadia Boubouchairopoulou, Ioannis Skiadas, Vasillios Tsekouras, Ana Cristina Hernandez Daly

  21-11-2022

  https://doi.org/10.4081/dr.2022.9265

  1582

  PDF: 474

  HTML: 37

• Cost analysis in the management of moderate-to-severe psoriasis: comparison between conventional and biological systemic therapies

  Edoardo Mortato, Silvia Baratta, Luca Rubino, Anna Paola De Caro, Francesco Loconsole

  19-06-2023

  https://doi.org/10.4081/dr.2023.9755

  909

  PDF: 443

  HTML: 25
• 

  Anti-interleukin-17 and anti-interleukin-23 biologic drugs for genital psoriasis: a single-center retrospective comparative study

  Andrea Cortese, Luigi Gargiulo, Luciano Ibba, Giovanni Fiorillo, Francesco Toso, Carlo Alberto Vignoli, Alessandra Narcisi, Antonio Costanzo, Mario Valenti

  19-05-2023

  https://doi.org/10.4081/dr.2023.9692

  1168

  PDF: 576

  HTML: 28
• 

  Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as inflammatory markers in psoriasis: a case-control study

  Hao Trong Nguyen, Long Dinh Hoang Vo, Nguyen Nhat Pham

  14-07-2022

  https://doi.org/10.4081/dr.2022.9516

  1762

  PDF: 755

  HTML: 29
• 

  Real-world use of dimethyl fumarate in patients with plaque psoriasis: a Delphi-based expert consensus

  Martina Burlando, Elena Campione, Aldo Cuccia, Giovanna Malara, Luigi Naldi, Francesca Prignano, Leonardo Zichichi

  29-12-2022

  https://doi.org/10.4081/dr.2023.9613

  1829

  PDF: 565

  HTML: 102

• Efficacy and safety of adalimumab biosimilar GP2017 in a 24-month treatment period for plaque psoriasis: real-life experience from Emilia-Romagna centers, Italy

  Marco May Lee, Vito Di Lernia, Francesca Peccerillo, Federico Bardazzi, Michela Tabanelli, Michela Ricci, Davide Melandri, Monica Corazza, Francesca Satolli, Andrea Conti

  01-07-2025

  https://doi.org/10.4081/dr.2025.10315

  633

  PDF: 326

  HTML: 25

• Increased serum interleukin-31 levels correlate with pruritus in psoriatic patients: a cross-sectional study in Vietnam

  Chuyen Thi Hong Nguyen, Liem Viet Quoc Tran

  27-11-2024

  https://doi.org/10.4081/dr.2024.10090

  883

  PDF: 430

  HTML: 33

• HLA-Cw6 increases the risk of psoriasis and early onset before twenty-seven years of age among the Vietnamese population

  Nhi Thi Uyen Pham, Thuong Van Nguyen, Hao Trong Nguyen

  16-10-2023

  https://doi.org/10.4081/dr.2023.9854

  1458

  PDF: 563

  HTML: 54

• Tildrakizumab in the treatment of plaque psoriasis in an HIV+ patient: a case report and literature review of anti-interleukin drugs

  Viviana Lora, Dario Graceffa, Monia Di Prete, Carlo Cota

  11-11-2024

  https://doi.org/10.4081/dr.2024.10140

  1093

  PDF: 579

  SUPPLEMENTARY MATERIAL: 188

  HTML: 24
• 

  Increased plasma lipocalin-2 levels correlate with disease severity and may be a marker of acute inflammatory response in patients with psoriasis

  Chuyen Thi Hong Nguyen, Oanh Phan Tram Nguyen

  21-11-2022

  https://doi.org/10.4081/dr.2022.9469

  1364

  PDF: 573

  HTML: 47

• A study on tumor necrosis factor-α single nucleotide polymorphisms and psoriasis vulgaris in Vietnam

  Vinh Ngo Minh, Thiên Phúc Lý, Hao Nguyen Trong, Chuong Nguyen Hoang

  12-04-2024

  https://doi.org/10.4081/dr.2024.9899

  1017

  PDF: 627

  HTML: 33

• 25 | EARLY AND MAINTAINED TREAT-TO-TARGET RESPONSE WITH IXEKIZUMAB UP TO 5 YEARS IN MODERATE-TO-SEVERE PSORIASIS: A POST-HOC ANALYSIS OF UNCOVER-3 E. Filippi¹, A. Armstrong², J. F. Merola³, M. Megna⁴, X. Man⁵, M. Honma⁶, J-M. Carrascosa⁷, R. Chughtai⁷, K. Fotiou⁸, S. Sabatino⁸, M. Ngantcha⁸, A. Pinter⁹ | ¹Eli Lilly Italia S.p.A, Florence, Italy; ²University of California, Los Angeles, CA, USA; ³University of Texas Southwestern Medical Center, Dallas, TX, USA; ⁴University of Naples Federico II, Naples, Italy; ⁵Zhejiang University, Hangzhou, China; ⁶Asahikawa Medical University, Asahikawa, Japan; ⁷Hospital Germans Trias, Universitat Autònoma de Barcelona, Barcelona, Spain; ⁸Eli Lilly and Company, Indianapolis, IN, USA; ⁹University Hospital Frankfurt, Frankfurt, Germany

  Associazione Dermatologi-Venereologi Ospedalieri Italiani e della Sanità Pubblica

  24-09-2026

  https://doi.org/10.4081/dr.2026.11087

  98

  PDF: 21

• The suitability of mesenchymal stem cells for treating immune-mediated inflammatory skin diseases: a systematic review

  Elena Pezzolo, Sara Di Leo, Paola Miceli, Alvise Sernicola, Luigi Naldi

  01-07-2025

  https://doi.org/10.4081/dr.2025.10112

  1028

  PDF: 768

  HTML: 40

• 24 | IXEKIZUMAB WITH OR WITHOUT TIRZEPATIDE IN ADULTS WITH PSORIASIS AND OVERWEIGHT OR OBESITY: THE TOGETHER-PSO PHASE 3B RANDOMIZED CLINICAL TRIAL E. Filippi¹, M. Lebwohl², A. Blauvelt³, C. Kartman⁴, C. Leatherwood⁴, K. Gordon⁵, N. Sattar⁶, L. Puig⁷, J. Merola⁸, K. Siu⁴, R. Wang⁴, L. Sun⁴, A. Leung⁹, N. Somani⁴, M. Rueda⁴, A. Cardoso⁴, M. Genovese⁴, A. Armstrong¹⁰, B. Strober¹¹ | ¹Eli Lilly Italy S.p.A, Sesto Fiorentino, Italy; ²Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; ³Blauvelt Consulting, LLC, Annapolis, MD, USA; ⁴Eli Lilly and Company, Indianapolis, IN, USA; ⁵Department of Dermatology, Medical College of Wisconsin, Milwaukee, WI, USA; ⁶School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, UK; ⁷Department of Dermatology, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona School of Medicine, Barcelona, Spain; ⁸Department of Dermatology and Department of Medicine, Division of Rheumatology, UT Southwestern Medical Center and O’Donnell School of Public Health, Dallas, TX, USA; ⁹Syneos Health, Morrisville, NC, USA; ¹⁰Division of Dermatology, University of California Los Angeles David Geffen School of Medicine, Los Angeles, CA, USA; ¹¹Department of Dermatology, Yale University School of Medicine, New Haven, CT, Central Connecticut Dermatology Research, Cromwell, CT, USA

  Associazione Dermatologi-Venereologi Ospedalieri Italiani e della Sanità Pubblica

  24-09-2026

  https://doi.org/10.4081/dr.2026.11086

  97

  PDF: 31

• Severe relapse of generalized psoriasis in a young patient with a Löfgren syndrome history

  Ermira Ziçishti, Migena Vargu, Sabina Dedej, Eriselda Kurushi, Valbona Zenelaj, Ermira Vasili

  13-03-2025

  https://doi.org/10.4081/dr.2025.10021

  537

  PDF: 362

  HTML: 15
• 

  Mycobacterium kansasii infection in a psoriasis patient treated with adalimumab and switch to apremilast: First report and literature review

  Alexandra Maria Giovanna Brunasso, Sanja Javor, Emanuele Pontali, Simona Sola, Cesare Massone

  29-07-2021

  https://doi.org/10.4081/dr.2021.8797

  3162

  PDF: 670

  HTML: 20
• 

  Guselkumab for the treatment of severe plaque psoriasis in a schizophrenia patient

  Nicoletta Bernardini, Nevena Skroza, Elisabeth Prevete, Federica Marraffa, Ilaria Proietti, Ersilia Tolino, Alessandra Mambrin, Giovanni Rossi, Salvatore Volpe, Giuseppe Bersani, Concetta Potenza

  23-11-2022

  https://doi.org/10.4081/dr.2022.9476

  1528

  PDF: 514

  HTML: 35
• 

  Seven cancer patients receiving guselkumab for treatment of moderate-to-severe psoriasis

  Luca Mastorino, Niccolò Siliquini, Gianluca Avallone, Michela Ortoncelli, Pietro Quaglino, Paolo Dapavo, Simone Ribero

  17-03-2022

  https://doi.org/10.4081/dr.2022.9282

  1230

  PDF: 865

  HTML: 49
• 

  Dimethyl fumarate as a safe and effective therapy for recalcitrant psoriasis in comorbid patients

  Martina Burlando, Mattia Fabio Molle, Emanuele Cozzani, Aurora Parodi

  14-03-2022

  https://doi.org/10.4081/dr.2022.9091

  2668

  PDF: 658

  HTML: 16
• 

  Long term efficacy, safety, and tolerability of tildrakizumab in epileptic patient with psoriasis and eczema

  Nicoletta Bernardini, Nevena Skroza, Giovanni Rossi, Alessandra Mambrin, Ersilia Tolino, Federica Marraffa, Martina Caviglia, Antonio Di Guardo, Salvatore Volpe, Ilaria Proietti, Concetta Potenza

  21-11-2022

  https://doi.org/10.4081/dr.2022.9447

  1431

  PDF: 432

  HTML: 54
• 

  Exacerbation of generalized plaque psoriasis after tuberculin test

  Alberto Corrà, Lavinia Quintarelli, Alice Verdelli, Walter Volpi, Marzia Caproni

  28-07-2021

  https://doi.org/10.4081/dr.2021.9019

  3210

  PDF: 534

  HTML: 306